Les signatures moléculaires commerciales: Quelle utilité clinique?

Suzette Delaloge; Mahasti Saghatchian; Amal Ghouadni; Mahmoud Fekih; Fabrice André

doi:10.1016/s0007-4551(15)31227-3

Les signatures moléculaires commerciales: Quelle utilité clinique?

Suzette Delaloge, Mahasti Saghatchian, Amal Ghouadni, Mahmoud Fekih, Fabrice André

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

2 Citations (Scopus)

Résumé

The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the key points for a rational use of commercial molecular signatures.

Titre traduit de la contribution	Molecular signatures of breast cancer: What clinical utility?
langue originale	Français
Pages (de - à)	S102-S105
journal	Bulletin du Cancer
Volume	102
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/s0007-4551(15)31227-3
état	Publié - 1 juin 2015

mots-clés

Breast cancer
Molecular signatures
Prediction
Prognosis

Accès au document

10.1016/s0007-4551(15)31227-3

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{097eead259c34bc99329db2d2a395640,

title = "Les signatures mol{\'e}culaires commerciales: Quelle utilit{\'e} clinique?",

abstract = "The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the key points for a rational use of commercial molecular signatures.",

keywords = "Breast cancer, Molecular signatures, Prediction, Prognosis",

author = "Suzette Delaloge and Mahasti Saghatchian and Amal Ghouadni and Mahmoud Fekih and Fabrice Andr{\'e}",

note = "Publisher Copyright: {\textcopyright} 2015 Soci{\'e}t{\'e} Fran{\c c}aise du Cancer. Publi{\'e} par Elsevier Masson SAS.",

year = "2015",

month = jun,

day = "1",

doi = "10.1016/s0007-4551(15)31227-3",

language = "Fran{\c c}ais",

volume = "102",

pages = "S102--S105",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "6",

}

TY - JOUR

T1 - Les signatures moléculaires commerciales

T2 - Quelle utilité clinique?

AU - Delaloge, Suzette

AU - Saghatchian, Mahasti

AU - Ghouadni, Amal

AU - Fekih, Mahmoud

AU - André, Fabrice

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the key points for a rational use of commercial molecular signatures.

AB - The role of molecular signatures in the adjuvant management of breast cancer remains a debated topic. Discussions should take into account the level of scientific validation, the impact on practice, the expected benefits and financing issues. This article presents the key points for a rational use of commercial molecular signatures.

KW - Breast cancer

KW - Molecular signatures

KW - Prediction

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84938070165&partnerID=8YFLogxK

U2 - 10.1016/s0007-4551(15)31227-3

DO - 10.1016/s0007-4551(15)31227-3

M3 - Article

C2 - 26118866

AN - SCOPUS:84938070165

SN - 0007-4551

VL - 102

SP - S102-S105

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 6

ER -